Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

Importance The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-
like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or …

The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous
semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term …

Obesity is a chronic, relapsing disease associated with multiple complications and a
substantial morbidity, mortality and health care burden. Pharmacological treatments for …

Aim To explore the safety and efficacy of subcutaneous semaglutide 2.4 mg, administered
once a week in non‐diabetic overweight or obese individuals. Methods A thorough search …

Background We assessed the efficacy and safety of the oral glucagon-like peptide-1
analogue, semaglutide 50 mg, taken once per day versus placebo for the treatment of …

Purpose This meta-analysis aimed to assess the efficacy and safety of once-weekly
semaglutide among adults with overweight or obesity. Methods We searched multiple …

Objective The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …

Aim To explore changes in body weight and cardiometabolic risk factors after treatment
withdrawal in the STEP 1 trial extension. Materials and Methods STEP 1 (NCT03548935) …

Abstract Background A once-weekly, 2.4-mg dose of subcutaneous semaglutide, a glucagon-
like peptide-1 receptor agonist, is used to treat obesity in adults, but assessment of the drug …